Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPIK-B5: Alpelisib + Fulvestrant in HR+, HER2- Advanced Breast Cancer
NCT05038735Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Dec 2021
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 17
01
Overview
A Phase 3 trial of alpelisib in breast cancer, sponsored by Novartis. Started Dec 2021; status: active, not recruiting.
02
Drugs
alpelisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05038735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05038735.